SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the only touchscreen insulin pumps available in the United States, today announced that one-third of t:slim X2™ Pump users have already updated their pumps via personal computer to add the new Dexcom G5® Mobile continuous glucose monitoring (CGM) integration. Tandem announced U.S. Food and Drug Administration approval and immediate launch of the CGM-enabled t:slim X2 Pump on August 28, 2017, including the associated software update for more than 12,000 customers who purchased a t:slim X2 Pump prior to the approval. Of the t:slim X2 Pump users who have taken advantage of the software update, more than 85% indicated they were satisfied or extremely satisfied with the update process.
“We are demonstrating our continued commitment to customer care by providing a simple, efficient and cost-effective way for people to keep up with our latest technology,” said Kim Blickenstaff, president and CEO of Tandem Diabetes Care. “We are the first and only company to offer its customers the ability to remotely update their insulin pump software using their personal computer. The rapid uptake and high satisfaction scores we’ve received since launch further validate our strategy and vision that modern technology can improve the lives of people with diabetes.”
“Tandem has brought diabetes technology into the future with their Tandem Device Updater,” said Dr. David Ahn, endocrinologist at the University of California, Los Angeles and Technology Editor at TCOYD. “Adding completely new features via software update from a personal computer has never been done in an insulin pump before, and it is amazing that people who received the very first t:slim X2 Pumps nearly one year ago now have the same new Dexcom G5® Mobile CGM integration available in the latest version shipping today.”
To learn more about the t:slim X2 Insulin Pump and its remote
software update capability, visit www.tandemdiabetes.com/tslimX2
or call (877) 801-6901, Monday – Friday between 6am and 5pm
Pacific Time
Download Tandem’s free t:simulator™ App to experience the touchscreen interface of the t:slim X2 Pump with Dexcom G5 Mobile CGM integration directly on your mobile device. For more information and to download the app, visit http://www.tandemdiabetes.com/tsimulator.
Information for Current t:slim X2 Pump Users
All eligible
t:slim X2 Pump users have the option to add Dexcom G5 Mobile CGM
integration via a software update using a personal computer.1
Individual emails have been sent directly to t:slim X2 Pump customers
with instructions on how to perform the update and their unique Update
ID number. The software update is Mac® and PC compatible. For more
information on system requirements, visit www.tandemdiabetes.com/updater.
Remote Software Updates for Insulin Pumps
Tandem is the only
company with a tool for providing remote software updates for its
insulin pumps using a personal computer. The power of the t:slim X2
Pump’s touchscreen allows for buttons to be moved and data like the
interactive CGM screen to be added via software updates without getting
a new device. With innovations in diabetes technology consistently
moving faster than the typical insurance pump replacement cycle, remote
software updates make it easier to make a purchasing decision today
without worrying that the device will soon be outdated. Future Tandem
products are being developed with software updates in mind, with the
goal of delivering new technologies to both new and current customers at
the same time.2
About Tandem Diabetes Care, Inc.
Tandem Diabetes Care, Inc. (www.tandemdiabetes.com)
is a medical device company dedicated to improving the lives of people
with diabetes through relentless innovation and revolutionary customer
experience. The Company takes an innovative, user-centric approach to
the design, development and commercialization of products for people
with diabetes who use insulin. Tandem manufactures and sells the t:slim
X2™ Insulin Pump, the only pump capable of remote feature updates using
a personal computer, and the t:flex® Insulin Pump, the first pump
designed for people with greater insulin requirements. Tandem is based
in San Diego, California.
Follow Tandem Diabetes Care on Twitter @tandemdiabetes; use #tslimX2,
#tflex, #tconnect, and $TNDM.
Follow Tandem Diabetes Care on
Facebook at www.facebook.com/TandemDiabetes.
Follow
Tandem Diabetes Care on LinkedIn at https://www.linkedin.com/company/tandemdiabetes.
Tandem Diabetes Care and t:flex are registered trademarks, and t:slim X2 and t:simulator are trademarks of Tandem Diabetes Care, Inc. Dexcom and Dexcom G5 are registered trademarks of Dexcom, Inc. All other trademarks are the property of their respective owners.
Forward Looking Statement
This press release contains
“forward-looking statements” within the meaning of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the Securities
Exchange Act of 1934, as amended, that concern matters that involve
risks and uncertainties that could cause actual results to differ
materially from those anticipated or projected in the forward-looking
statements. These forward-looking statements include statements
regarding the Company’s ability to develop and deploy future software
updates and deliver new technologies to both new and current customers
at the same time. The Company's actual results may differ materially
from those indicated in these forward-looking statements due to numerous
risks and uncertainties, including the Company’s ability to complete the
development of automated insulin delivery algorithms for the t:slim X2,
the Company’s ability to successfully complete clinical trials for new
products when anticipated (or at all), the potential that the results of
any such clinical trials may not be sufficient to support regulatory
approvals for new products as anticipated and the Company’s ability to
obtain regulatory approvals for future products and product features
generally. Other risks and uncertainties are identified in the Company’s
most recent Annual Report on Form 10-K and Quarterly Report on Form
10-Q, and other documents that the Company files with the Securities and
Exchange Commission. Investors are cautioned not to place undue reliance
on these forward-looking statements, which speak only as of the date of
this release. Tandem undertakes no obligation to update or review any
forward-looking statement in this press release because of new
information, future events or other factors.
1 Dexcom G5 Mobile CGM sold separately. CGM coverage may vary
based on insurance. Please consult your CGM supplier for coverage
information.
2 Additional feature updates are not
currently available for the t:slim X2 Pump with Dexcom G5 CGM
integration and are subject to future FDA approvals.
